Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-13 4:05 pm Purchase | 2025-06-30 | 13G | BioCardia, Inc. BCDA | Thomas A. Satterfield, Jr. | 592,144 9.900% | 203,997 (+52.56%) | Filing History |
| 2025-08-13 4:05 pm Purchase | 2025-06-30 | 13G | OS Therapies Incorporated OSTX | Thomas A. Satterfield, Jr. | 3,115,681 9.400% | 1,848,216 (+145.82%) | Filing History |
| 2025-08-07 4:05 pm Purchase | 2025-08-05 | 13G | Ark Restaurants Corp. ARKR | Thomas A. Satterfield, Jr. | 622,292 17.300% | 48,041 (+8.37%) | Filing History |
| 2025-08-07 08:00 am Purchase | 2025-06-30 | 13G | inTEST Corporation INTT | Thomas A. Satterfield, Jr. | 1,000,594 8.000% | 195,594 (+24.30%) | Filing History |
| 2025-04-16 5:37 pm Purchase | 2025-04-14 | 13G | Coherus BioSciences, Inc. CHRS | Thomas A. Satterfield, Jr. | 6,009,514 5.200% | 6,009,514 (New Position) | Filing History |
| 2025-04-16 5:36 pm Purchase | 2025-03-31 | 13G | Curis, Inc. CRIS | Thomas A. Satterfield, Jr. | 1,035,762 9.900% | 245,330 (+31.04%) | Filing History |
| 2025-02-18 4:15 pm Sale | 2025-02-13 | 13G | Edesa Biotech, Inc. EDSA | Thomas A. Satterfield, Jr. | 0 0.000% | -232,161 (Position Closed) | Filing History |
| 2025-02-12 08:02 am Sale | 2024-12-31 | 13G | OS Therapies Incorporated OSTX | Thomas A. Satterfield, Jr. | 1,267,465 5.900% | -27,524 (-2.13%) | Filing History |
| 2025-02-12 08:02 am Purchase | 2024-12-31 | 13G | inTEST Corporation INTT | Thomas A. Satterfield, Jr. | 805,000 6.500% | 135,000 (+20.15%) | Filing History |
| 2025-02-12 08:01 am Purchase | 2024-12-31 | 13G | Ark Restaurants Corp. ARKR | Thomas A. Satterfield, Jr. | 574,251 15.900% | 38,694 (+7.23%) | Filing History |
| 2025-02-12 08:00 am Purchase | 2024-12-31 | 13G | Scientific Industries, Inc. SCND | Thomas A. Satterfield, Jr. | 1,138,055 9.900% | 541,100 (+90.64%) | Filing History |
| 2025-02-12 08:00 am Purchase | 2024-12-31 | 13G | Edesa Biotech, Inc. EDSA | Thomas A. Satterfield, Jr. | 232,161 6.700% | 56,117 (+31.88%) | Filing History |
| 2025-02-12 08:00 am Purchase | 2024-12-31 | 13G | Curis, Inc. CRIS | Thomas A. Satterfield, Jr. | 790,432 9.100% | 100,000 (+14.48%) | Filing History |
| 2025-02-12 08:00 am Purchase | 2024-12-31 | 13G | BioCardia, Inc. BCDA | Thomas A. Satterfield, Jr. | 388,147 8.200% | 388,147 (New Position) | Filing History |
| 2025-01-17 4:05 pm Purchase | 2025-01-13 | 13G | Cytosorbents Corporation CTSO | Thomas A. Satterfield, Jr. | 3,998,867 6.560% | 3,998,867 (New Position) | Filing History |
| 2024-11-01 4:35 pm Purchase | 2024-10-30 | 13G | Curis, Inc. CRIS | Thomas A. Satterfield, Jr. | 690,432 8.050% | 690,432 (New Position) | Filing History |
| 2024-09-24 07:00 am Purchase | 2024-09-18 | 13G | inTEST Corporation INTT | Thomas A. Satterfield, Jr. | 670,000 5.350% | 630,539 (+1597.88%) | Filing History |
| 2024-08-28 4:30 pm Purchase | 2024-08-02 | 13G | OS Therapies Incorporated OSTX | Thomas A. Satterfield, Jr. | 1,294,989 6.200% | 1,294,989 (New Position) | Filing History |
| 2024-06-03 4:10 pm Purchase | 2024-05-30 | 13G | Edesa Biotech, Inc. EDSA | Thomas A. Satterfield, Jr. | 176,044 5.470% | 176,044 (New Position) | Filing History |
| 2024-02-14 5:06 pm Purchase | 2023-12-31 | 13G | BioCardia, Inc. BCDA | Thomas A. Satterfield, Jr. | 113,400 7.870% | 37,426 (+49.26%) | Filing History |